Appointment underscores Champions&#39; focus on leveraging clinically relevant data to power next-generation oncology R&amp;DHACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading

<p><i><strong>Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D</strong></i></p><p><strong id="dateline">HACKENSACK, NJ / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 30, 2026 / </strong><strong>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CSBR">CSBR</a>)</strong>, a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development.</p><p>Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology and improve R&D outcomes. Dr. Alexander's appointment reflects the Company's continued investment in this capability and its evolution toward a more connected translational research platform.</p><p>"Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris, Chairman of the Board at Champions Oncology. "As we continue to expand our data capabilities, his perspective will help us better link tumor models with multi-omic and patient data, accelerate discovery, and support more efficient clinical development."</p><p>"I'm excited to join Champions at an important point in its evolution," said Dr. Alexander. "The ability to connect well characterized tumor models with rich datasets creates a powerful opportunity to deepen our understanding of disease and enable more informed therapeutic development. I look forward to working with the team to advance this approach."</p><p>Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors with comprehensive molecular and clinical data. This approach enhances its ability to support partners across the oncology R&D continuum, from early discovery through translational development, with a more data-informed and analytically driven strategy.</p><p>To learn more about how Champions Data Services powers oncology drug discovery, visit: <a rel="nofollow" href="https://pr.report/k81l">https://www.championsoncology.com/data-ecosystem</a></p><p><strong>About Champions Oncology</strong></p><p>Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative, highest-quality data through proprietary in vivo and ex vivo platforms. Utilizing its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit <a rel="nofollow" href="https://pr.report/c1vz"><u>www.ChampionsOncology.com</u></a>.</p><p>Contact:<br/>Gavin Cooper - Vice President of Global Marketing<br/><a rel="nofollow" href="mailto:gcooper@championsoncology.com">gcooper@championsoncology.com</a><br/>+1 (518) 488 9062</p><p><strong>SOURCE:</strong> Champions Oncology, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/champions-oncology-names-brian-alexander-to-board-as-company-advances-1152984'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1152984" width="0" height="0"/>

CSBR

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology Expands Board with Data Science Expert Brian Alexander

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Appointment underscores Champions&amp;#39; focus on leveraging clinically relevant data to power next-generation oncology R&amp;amp;DHACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Champions Oncology has appointed Dr. Brian Alexander to its Board of Directors, signaling a commitment to enhancing its data capabilities in oncology research. This strategic move aims to improve drug discovery through the integration of clinically relevant datasets, likely accelerating development timelines and R&amp;D efficiency.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Champions Oncology appoints Dr. Brian Alexander to its Board of Directors.</li><li>Dr. Alexander has extensive experience in oncology and data science.</li><li>Champions emphasizes connecting tumor models with clinical datasets for R&amp;D.</li><li>Advanced analytics and AI will improve drug discovery and development.</li><li>This appointment aligns with Champions&#039; strategic investment in data capabilities.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Valo Health (N/A)</strong>: Dr. Alexander&#039;s previous experience may enhance partnerships in drug development.</li><li><strong>Foundation Medicine (N/A)</strong>: Previous affiliations with this organization could influence CSBR&#039;s data analytics approach.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits within &#039;Corporate Developments&#039; as it focuses on a significant management change aimed at enhancing Champions Oncology&#039;s strategic direction in oncology R&amp;D. The appointment of a data science expert underlines the company&#039;s intent to leverage clinical data for competitive advantage.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Dr. Alexander&#039;s appointment could attract new partnerships in drug development.</li><li>Improved data capabilities may lead to increased revenue from R&amp;D services.</li><li>Potential for significant advancements in drug discovery timelines affecting market positioning.</li><li>AI-driven analytics could enhance operational efficiency and reduce costs.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Brian Alexander holds MD, MPH degrees and has leadership experience in leading biotech firms.</li><li>Champions boasts the largest collection of patient-derived xenograft models in oncology.</li><li>Companies&#039; focus will be on integrating tumor models with molecular and clinical data.</li><li>The appointment reflects Champions&#039; strategic evolution towards data-driven drug development.</li><li>Champions has been positioning itself as a leader in oncology R&amp;D services.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in CSBR for medium-term growth based on enhanced R&amp;D capabilities and data integration.</p>
  </section>
</section>


<p><i><strong>Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D</strong></i></p><p><strong id="dateline">HACKENSACK, NJ / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / March 30, 2026 / </strong><strong>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CSBR">CSBR</a>)</strong>, a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development.</p><p>Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology and improve R&D outcomes. Dr. Alexander's appointment reflects the Company's continued investment in this capability and its evolution toward a more connected translational research platform.</p><p>"Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris, Chairman of the Board at Champions Oncology. "As we continue to expand our data capabilities, his perspective will help us better link tumor models with multi-omic and patient data, accelerate discovery, and support more efficient clinical development."</p><p>"I'm excited to join Champions at an important point in its evolution," said Dr. Alexander. "The ability to connect well characterized tumor models with rich datasets creates a powerful opportunity to deepen our understanding of disease and enable more informed therapeutic development. I look forward to working with the team to advance this approach."</p><p>Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors with comprehensive molecular and clinical data. This approach enhances its ability to support partners across the oncology R&D continuum, from early discovery through translational development, with a more data-informed and analytically driven strategy.</p><p>To learn more about how Champions Data Services powers oncology drug discovery, visit: <a rel="nofollow" href="https://pr.report/k81l">https://www.championsoncology.com/data-ecosystem</a></p><p><strong>About Champions Oncology</strong></p><p>Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative, highest-quality data through proprietary in vivo and ex vivo platforms. Utilizing its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit <a rel="nofollow" href="https://pr.report/c1vz"><u>www.ChampionsOncology.com</u></a>.</p><p>Contact:<br/>Gavin Cooper - Vice President of Global Marketing<br/><a rel="nofollow" href="mailto:gcooper@championsoncology.com">gcooper@championsoncology.com</a><br/>+1 (518) 488 9062</p><p><strong>SOURCE:</strong> Champions Oncology, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/champions-oncology-names-brian-alexander-to-board-as-company-advances-1152984'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1152984" width="0" height="0"/>

Champions Oncology has appointed Dr. Brian Alexander to its Board of Directors, signaling a commitment to enhancing its data capabilities in oncology research. This strategic move aims to improve drug discovery through the integration of clinically relevant datasets, likely accelerating development timelines and R&D efficiency.

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News